Your API crystallized reliably for eighteen months. Then, with no change to the synthesis route, the plant stopped producing the original crystal form — and every batch since has come out different. If that sounds familiar, you’re dealing with one of solid-state chemistry’s most disruptive phenomena: the disappearing polymorph, and it is a program management problem long before it is a lab problem.
When the Crystal You Validated Stops Forming
Most solid-form surprises happen quietly. A scale-up batch takes longer to filter. A dissolution result drifts outside spec. A stability sample that passed six months ago now shows a new peak on XRPD. None of these look like a crisis on their own.
The common thread, when teams finally trace the root cause, is that the compound has settled into a different, usually more thermodynamically stable, crystal form — and the original form has become difficult or impossible to reproduce under the same conditions that once generated it reliably.
This is not a rare lab anomaly confined to academic papers. It is a recognized risk category in small molecule development, and it has derailed regulatory filings, manufacturing campaigns, and supply commitments for companies with far more resources than most emerging biotechs.
What "Disappearing" Actually Means (and What It Doesn’t)
Many small molecules can adopt more than one crystal structure — these are polymorphs. Each form can have different solubility, dissolution rate, stability, and processability, even though the molecule itself is identical.
A "disappearing polymorph" is what happens when a previously accessible form becomes effectively unobtainable, typically because a more stable form has started to dominate the crystallization environment — in the plant, in the lab, or even across an industry once seed crystals of the new form have spread.
It is not that the original form becomes scientifically impossible. It is that, in practice, re-establishing the conditions that originally produced it can range from difficult to commercially unviable once the environment has shifted.
For a program manager, the technical mechanism matters less than the consequence: the solid form your formulation, your dissolution method, and possibly your regulatory filing were built around may no longer be the form your plant is producing.
Why This Belongs on a Program Risk Register
A solid-form change is rarely just a quality deviation. It cascades through the program in several directions at once, and each one carries a cost and a timeline impact that procurement and business development leaders need to price in.
The most immediate exposure is supply continuity. If a contract manufacturer cannot reliably reproduce the qualified form, batch release is delayed or batches are rejected, and clinical supply or commercial shipments slip.
The second exposure is regulatory. Bioavailability, dissolution profile, and stability data are typically tied to a specific solid form in the filing. A form change can trigger bridging studies, additional stability data, or in the worst case, questions from regulators about comparability.
The third exposure is intellectual property. Solid-form patents are a recognized strategy for extending product life cycles; losing control of which form your process reliably produces can weaken a freedom-to-operate position or complicate a defensive patent strategy.
The fourth, and often underestimated, exposure is simple cost of re-work: re-screening, re-validating analytical methods, and re-qualifying a manufacturing process on a compressed timeline is materially more expensive than doing comprehensive screening once, early, under controlled conditions.
The Industry’s Cautionary Tale
The best-known public example of a disappearing polymorph involves an HIV protease inhibitor that, after launch, began producing a new, less soluble crystal form during manufacturing — a change serious enough to force a temporary market withdrawal and reformulation of the product.
The case is widely cited in the solid-state chemistry literature not because it was unusual, but because it was well documented and highly visible. Less dramatic versions of the same story occur more often than public records suggest, typically resolved quietly during development rather than after launch.
The lesson for program managers is not that polymorphism is unmanageable. It is that the companies who manage it well treat solid-form risk as a planned workstream with a budget and a timeline, not as a contingency they hope never materializes.
Timing the Investment: Early Screening vs. Late Discovery
The decision that matters most is not whether to screen for polymorphs — most development teams accept that some screening is necessary — but when and how thoroughly.
Screening conducted early, before a lead form is locked into formulation and analytical method development, is comparatively inexpensive and low-pressure. It can explore a wide range of crystallization conditions, solvents, and stress environments without the cost of disrupting an established process.
Screening conducted late — after a form change has already been detected in a stability chamber or a scale-up batch — happens under time pressure, against a filing deadline or a supply commitment, and usually costs several times more in both direct spend and opportunity cost.
For procurement and BD leaders evaluating outsourcing proposals, this is the real comparison to make: a modest, well-scoped screening investment at candidate selection versus an unplanned, urgent engagement later in the program, negotiated from a position of reduced leverage.
What a Defensible Solid-Form Strategy Looks Like
Teams that manage this risk well share a common set of practices, regardless of company size. None of these require exotic infrastructure — they require discipline and a partner who treats solid-state work as a primary competency rather than a box to tick.
A defensible strategy typically includes the following elements, applied in proportion to the stage of development and the risk profile of the molecule.
- A polymorph landscape study conducted early, covering a representative range of solvents, cooling rates, and crystallization methods, not a single default protocol
- Stability screening under realistic storage, humidity, and mechanical stress conditions to flag form changes before they appear in a stability chamber at month 6
- Characterization with more than one orthogonal technique — XRPD alongside DSC/TGA or solid-state NMR — since a single method can miss subtle or low-level form changes
- A documented, retrievable record of which forms were observed and under what conditions, so that if a new form appears, the team can distinguish a genuine disappearing-polymorph event from a process or impurity issue
- Contingency planning: knowing in advance which backup form, salt, or co-crystal could serve as an alternative if the primary form becomes difficult to reproduce
The Outsourcing Decision: What to Look For in a Partner
Few organizations — including large pharma R&D groups — maintain the full breadth of solid-state characterization capability in-house across every program. Outsourcing this work is not a sign of under-resourcing; it is a recognized, efficient way to access specialized expertise without building permanent infrastructure for a capability used intermittently.
The decision that matters for procurement is which partner to choose, and the criteria go beyond instrument lists. A CRO with genuine depth in crystal engineering will design a screening protocol around the specific molecule and risk profile rather than running a generic template.
For high-potency compounds or controlled substances, the evaluation has an additional layer: does the partner hold the containment infrastructure and the regulatory authorizations needed to handle the material at all, without creating a second bottleneck in the program.
Practical criteria worth putting into any CRO selection scorecard include GMP certification and inspection history, breadth of orthogonal analytical techniques available under one roof, documented containment capability for OEB4/OEB5 compounds where relevant, authorization to handle controlled substances where relevant, and a track record of tailoring protocols rather than applying one-size-fits-all packages.
Disappearing polymorphs are a known, manageable risk — but only if the decision to invest in solid-form characterization is made deliberately and early, rather than reactively after a batch fails. PCL Research & Manufacturing works with development teams at exactly this decision point, combining solid-state chemistry expertise rooted in academic crystal engineering with GMP-certified, FDA-inspected infrastructure and the containment and regulatory authorizations needed for high-potency and controlled compounds. If your program is approaching a candidate selection milestone, or if a form change has already appeared in your data, we’re glad to talk through what a proportionate screening strategy would look like for your specific molecule.
